Updated: January 19, 2026
Solu-Cortef Shortage: What Providers and Prescribers Need to Know in 2026

- Current Supply Status (2026)
- Shortage Chronology: 2023 Through 2025
- Therapeutic Alternatives: Clinical Considerations
- Indications Where Mineralocorticoid Activity Is Critical
- Indications Where Mineralocorticoid Activity Is Not Required
- Generic Substitution: A-Hydrocort
- Protocols for Adrenal Insufficiency Patients: Home Emergency Kit Access
- Resources for Providers
Overview
A clinical guide for providers on the Solu-Cortef shortage history, current supply status, therapeutic alternatives, and how to support patients in 2026.
Is Solu-Cortef in stock near you?
Based on 58 real pharmacy checks · 3 patients helped
Verified 1h ago
Hydrocortisone sodium succinate (Solu-Cortef) is a foundational drug in emergency medicine, endocrinology, critical care, and rheumatology. Its recurring supply disruptions — most prominently in 2023 and again in 2025 — have forced providers to develop contingency protocols, substitute regimens, and patient communication strategies. This guide provides a comprehensive clinical overview for prescribers managing Solu-Cortef access challenges in 2026.
Current Supply Status (2026)
As of October 2025, the ASHP confirmed that Pfizer has all Solu-Cortef presentations available, and no active FDA drug shortage is designated heading into 2026. All vial strengths — 100 mg, 250 mg, 500 mg, and 1,000 mg ACT-O-VIAL presentations, as well as the 100 mg plain vial — have been restored to general availability through wholesalers and distributors.
However, localized stocking inconsistencies remain possible, particularly at retail pharmacies supplying home emergency kits for adrenal insufficiency patients. Providers should not assume uniform access across all dispensing channels.
Check live stock now.
Shortage Chronology: 2023 Through 2025
March 2023: Pfizer announced a supply disruption for Solu-Cortef 100 mg/2 mL ACT-O-VIAL Single Dose Vials (NDC 00009-0011-03 and 00009-0011-04) secondary to quality issues and demand surge. All inventory restricted to direct-order allocation to institutions with purchase history. FDA notified. Pfizer Supply Continuity Team activated.
May 2023: FDA issued emergency expiration date extension for 32 lots — extended five months beyond the labeled 36-month shelf life. Recovery initially projected for June 2023, later extended to December 2023.
April 2025: Pfizer notified of a second short-term interruption in the 25-pack presentation (NDC 00009-0011-04) due to increased demand and a manufacturing delay that had been resolved. Recovery projected Q3 2025. FDA notified. 1-vial presentation (NDC 00009-0011-03), 250 mg, 500 mg, and 1,000 mg presentations maintained at 100-125% of baseline allocation.
October 2025: ASHP database updated: all presentations available; shortage formally resolved.
Therapeutic Alternatives: Clinical Considerations
When Solu-Cortef is unavailable, the choice of alternative depends critically on the underlying clinical indication. The key distinction is whether mineralocorticoid activity is required:
Indications Where Mineralocorticoid Activity Is Critical
For patients with primary adrenal insufficiency (Addison's disease) or congenital adrenal hyperplasia (CAH), hydrocortisone's mineralocorticoid activity is essential during stress-dosing and adrenal crisis management. If Solu-Cortef or its generic (A-Hydrocort) is unavailable:
Dexamethasone sodium phosphate or methylprednisolone sodium succinate may serve as glucocorticoid substitutes but require supplemental fludrocortisone to address mineralocorticoid deficiency in primary adrenal failure
Dose conversion: 100 mg hydrocortisone ≈ 20 mg methylprednisolone ≈ 4 mg dexamethasone (glucocorticoid equivalence only — no mineralocorticoid effect)
Hydrocortisone's biological half-life is 8–12 hours; dexamethasone's is 36–72 hours — dose frequency must be adjusted accordingly
Indications Where Mineralocorticoid Activity Is Not Required
For severe allergic reactions, asthma exacerbations, autoimmune flares, and other inflammatory indications in patients with intact adrenal function, dexamethasone or methylprednisolone sodium succinate (Solu-Medrol) are clinically appropriate substitutes. Solu-Medrol is preferred over Solu-Cortef for extended high-dose therapy (beyond 48-72 hours) due to lower sodium retention.
Generic Substitution: A-Hydrocort
A-Hydrocort (hydrocortisone sodium succinate injection, generic) is the simplest and most appropriate first-line substitute for Solu-Cortef. It is therapeutically equivalent, available in the same strengths, and typically priced lower. Prescribers should note that if brand and generic share the same manufacturing source, both may be simultaneously unavailable during a Pfizer-specific disruption — in that scenario, the alternatives above become necessary.
Found
Rate
on average
Protocols for Adrenal Insufficiency Patients: Home Emergency Kit Access
Patients with adrenal insufficiency presenting for routine refills of home emergency kits require special attention during shortage periods. Recommended provider actions:
Proactive prescribing: Prescribe refills well before expiration. Consider prescribing backup kits for high-risk patients.
Hospital pharmacy routing: Route prescriptions through hospital pharmacies with direct Pfizer purchasing relationships during retail-level shortages.
503B compounding pharmacies: FDA-registered 503B compounders can prepare hydrocortisone sodium succinate injection as a shortage alternative.
Patient education: Ensure all adrenal insufficiency patients have updated sick-day rules, current emergency kit instructions, and know to go directly to an ER if they cannot obtain Solu-Cortef during a crisis.
Resources for Providers
ASHP Drug Shortage Database: ashp.org/drug-shortages — real-time shortage status and clinical guidance
Pfizer Supply Continuity Team: 1-844-646-4398, option 1 (Customer) then option 3 (Supply Continuity), M-F 7 a.m.-5 p.m. CT
Pfizer Hospital Availability Report: PfizerHospitalUS.com — updated frequently with product-level availability data
medfinder also offers a provider-facing service to help your patients locate in-stock pharmacies near them. Visit medfinder for providers to learn more.
See also: How to help your patients find Solu-Cortef in stock — a provider's guide.
Real-time availability
Is Solu-Cortef in stock near you?
Verified 1h ago
Based on 58 real pharmacy checks · 3 patients helped
Solu-Cortef is in a shortage right now — Medfinder calls pharmacies near you to track down the ones that have it.
As of November 17, 2026, 1:00 AM ET, Solu-cortef is currently experiencing a shortage. Across 58 pharmacy checks Medfinder placed in the last 30 days, Solu-cortef was confirmed in stock 3% of the time.
- Pharmacy checks
- 58
- FDA status
- Not listed
- Updated
- 1h ago
Solu-cortef is not on the FDA's active shortage list. Medfinder's own pharmacy calls put real-time availability at 3% across 58 checks in the last 30 days. Availability varies by metro, with the most pharmacy activity recorded around San Francisco, CA. These numbers are recomputed continuously from live pharmacy calls, so this page reflects current conditions rather than a static estimate.
Where Solu-Cortef is easiest to find
| Metro | In-stock rate | Checks |
|---|---|---|
| San Francisco, CA | 4% | 28 |
Solu-Cortef availability questions
Is Solu-cortef in stock right now?
As of November 17, 2026, 1:00 AM ET, Solu-cortef was confirmed in stock at 3% of 58 pharmacies Medfinder checked in the last 30 days. Availability changes daily, so we re-check in real time when you search.
How does Medfinder help me find Solu-cortef?
Medfinder calls pharmacies in your area to verify whether Solu-cortef and your specific dose are in stock, then sends you the pharmacy name, address, and phone number.
Need Solu-Cortef? We'll find the pharmacy that has it.
Sources: FDA Drug Shortages + Medfinder pharmacy data · Methodology · Full Solu-Cortef data
Frequently Asked Questions
Yes. As of October 2025, Pfizer confirmed that all Solu-Cortef presentations are available through wholesalers and distributors. The ASHP updated the shortage entry to reflect resolved status. Providers should still monitor their distributor's Pfizer Hospital Availability Report for real-time allocation data.
In terms of glucocorticoid potency, 0.75 mg dexamethasone is approximately equivalent to 20 mg hydrocortisone. For stress-dosing in adrenal insufficiency, 4 mg dexamethasone IV/IM is sometimes used as an emergency substitute. Note that dexamethasone has no mineralocorticoid activity, so fludrocortisone must be added for primary adrenal insufficiency patients.
Yes. FDA-registered 503B outsourcing facilities can compound hydrocortisone sodium succinate for injection as an alternative source during Solu-Cortef shortages. Prescribers should confirm the facility is FDA-registered and that the preparation meets USP standards. Institutional purchasing agreements may also facilitate access.
Per FDA prescribing information, high-dose hydrocortisone therapy should not exceed 48–72 hours due to risk of hypernatremia from its mineralocorticoid activity. When extended high-dose corticosteroid therapy is required beyond that window, switching to methylprednisolone sodium succinate (Solu-Medrol) is recommended, as it causes little to no sodium retention.
Providers should advise patients to begin refill outreach 2–3 weeks before the kit expires, ask about A-Hydrocort (generic equivalent) availability at multiple pharmacies, and have a clear action plan if the kit cannot be obtained — including the nearest ER location and a medical alert card. Sick-day rules and stress-dose instructions should be reviewed at every endocrinology visit.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Solu-Cortef also looked for:
More about Solu-Cortef
48,324 have already found their meds with Medfinder.
Start your search today.
Your information is private and never shared.





